Related Experiment Videos
Substituted acrylamides as factor Xa inhibitors: improving bioavailability by P1 modification.
Yonghong Song1, Lane Clizbe, Chhaya Bhakta
1Millennium Pharmaceuticals, Inc., South San Francisco, CA 94080, USA. yonghong.song@mpi.com
Bioorganic & Medicinal Chemistry Letters
|July 13, 2002
Summary
New Factor Xa inhibitors with aminoisoquinoline groups show improved oral bioavailability and potency. Modifications to the P4 moiety further enhance their pharmacokinetic properties for potential therapeutic use.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Drug Discovery
Background:
- Previous substituted acrylamide P1 benzamidine inhibitors of Factor Xa exhibited low oral bioavailability.
- The benzamidine group contributed to poor pharmacokinetic properties, limiting therapeutic potential.
Purpose of the Study:
- To develop novel Factor Xa inhibitors with enhanced oral bioavailability.
- To identify potent, selective, and orally bioavailable Factor Xa inhibitors by modifying the P1 and P4 moieties.
Main Methods:
- Synthesis of a series of P1 aminoisoquinoline substituted acrylamide compounds.
- Evaluation of inhibitor potency and selectivity against Factor Xa.
- Assessment of oral bioavailability and pharmacokinetic properties in preclinical models.
Main Results:
- The P1 aminoisoquinoline substitution successfully replaced the benzamidine group, overcoming bioavailability issues.
- The identified compounds demonstrated potent and selective inhibition of Factor Xa.
- These inhibitors were found to be orally bioavailable.
- Further modification of the P4 moiety led to significant improvements in pharmacokinetic profiles.
Conclusions:
- P1 aminoisoquinoline substituted acrylamides represent a promising class of orally bioavailable Factor Xa inhibitors.
- Strategic modification of inhibitor scaffolds can effectively address bioavailability challenges.
- These findings pave the way for the development of effective anticoagulants targeting Factor Xa.